| Company Name: |
ChemShuttle, Inc.
|
| Tel: |
0510-83588313-811 18800520310 |
| Email: |
sales@chemshuttle.com |
| Products Intro: |
Product Name:2-(4-(2-(benzyloxy)acetyl)piperazin-1-yl)benzonitrile
CAS:1242443-29-3
Purity:95% Package:5mg;25mg;100mg;500mg;1g;5g;10g;25g;50g;100g;250g;500g;kg…
|
2-(4-(2-(Benzyloxy)acetyl)piperazin-1-yl)benzonitrile manufacturers
- VU0364289
-
- $1520.00
-
2026-04-20
- CAS:1242443-29-3
- Purity:
- Supply Ability: 10g
|
| | 2-(4-(2-(Benzyloxy)acetyl)piperazin-1-yl)benzonitrile Basic information |
| | 2-(4-(2-(Benzyloxy)acetyl)piperazin-1-yl)benzonitrile Chemical Properties |
| Boiling point | 552.0±50.0 °C(Predicted) | | density | 1.23±0.1 g/cm3(Predicted) | | pka | 1.30±0.10(Predicted) | | form | Solid | | color | Yellow to brown |
| | 2-(4-(2-(Benzyloxy)acetyl)piperazin-1-yl)benzonitrile Usage And Synthesis |
| Description | VU0364289 is a novel N-aryl piperazine mGlu5 positive allosteric modulator. | | Uses | VU0364289 is a highly selective mGlu5 positive allosteric modulator (PAM) (binds to the MPEP (HY-14609A) site), with an EC50 of 1.6 μM. VU0364289 can reverse amphetamine-induced hyperlocomotion in a dose-dependent manner, which can be used for schizophrenia and other psychiatric research[1][2][3]. | | in vivo | VU0364289 (10, 30, 56.6, 100 mg/kg ; i.p.; once) reverse amphetamine-induced hyperlocomotion in a dose-dependent manner, and (56.6, 100 mg/kg) shows significantly fewer ambulations[1].
VU0364289 (10 mg/kg; i.p.; once) is rapidly and significantly absorbed in rats, and shows excellent central nervous system penetration[1]. | Animal Model: | Adult male Sprague-Dawley rats (250-275 g)[1]. | | Dosage: | 10, 30, 56.6, 100 mg/kg | | Administration: | Intraperitoneal injection; once. | | Result: | Showed activity of reversing the hyperlocomotion induced by amphetamine, and can also significantly fewer ambulations in rats when dose up to 56.6 mg/kg. |
| Animal Model: | Adult male Sprague-Dawley rats (250-275 g)[1]. | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection; once. | | Result: | 1.19Pharmacokinetic Parameters of VU0364289 in male Sprague-Dawley rats[1].
| Tmax (h) | Cmax (ng/mL) | Plasma protein binding | Rat Fu (free fraction) | | IP (10 mg/kg) | 0.25 | 1280 | 94% (h); 90% (r) | 0.10 |
|
| | IC 50 | mGlu5: 1.6 μM (EC50) | | References | [1] Gregory KJ, et al. N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement. J Pharmacol Exp Ther. 2013 Nov;347(2):438-57. DOI:10.1124/jpet.113.206623
[2] Ya Zhou, et al. Discovery of N-Aryl Piperazines as Selective mGluR5Potentiators with Improved In Vivo Utility. ACS medicinal chemistry letters, 2010, 1(8): 433-438.
[3] Psychosis Models[M]//Melatonin, Neuroprotective Agents and Antidepressant Therapy. Springer, New Delhi, 2016: 731-750. |
| | 2-(4-(2-(Benzyloxy)acetyl)piperazin-1-yl)benzonitrile Preparation Products And Raw materials |
|